Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2022 08:22 ET | Source: Silo Pharma, Inc.

Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation Englewood Cliffs NJ, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a...
December 14, 2021 08:07 ET | Source: Silo Pharma, Inc.

Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced...
December 02, 2021 08:10 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

Englewood Cliffs NJ, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the...
November 18, 2021 09:45 ET | Source: Silo Pharma, Inc.

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
November 11, 2021 08:09 ET | Source: Silo Pharma, Inc.

Silo Pharma Reports Third Quarter Results and Operating Highlights

Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
October 27, 2021 08:11 ET | Source: Silo Pharma, Inc.

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

Englewood Cliffs NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
October 07, 2021 08:11 ET | Source: Silo Pharma, Inc.

Silo Pharma achieves milestone - Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

Englewood Cliffs NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
August 25, 2021 08:01 ET | Source: Silo Pharma, Inc.

Silo Pharma Advances Psychedelic Patent Portfolio

Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
August 11, 2021 08:10 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
July 27, 2021 08:08 ET | Source: Silo Pharma, Inc.

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right